BioRestorative to Provide a Positive FDA Update on Clinical Pipeline
BioRestorative Therapies (NASDAQ:BRTX) has announced it will provide a positive clinical pipeline update before market open on Thursday, February 27, 2025. The regenerative medicine company, which focuses on stem cell-based therapies, will share what CEO Lance Alstodt describes as "meaningful key developments" regarding their clinical pipeline.
Alstodt expressed enthusiasm about the upcoming announcement, noting that it reflects "the very solid work of our scientific team over the last several years come to fruition" and mentioned additional positive events related to BRTX-100, one of the company's products.
The company will host a webcasted conference call at 8:00am EST on February 27, 2025, accessible by dialing 888-506-0062 (US) or 973-528-0011 (International) with participant access code 440089. The call will also be broadcast live and archived on the Investor section of BioRestorative's website.
BioRestorative Therapies (NASDAQ:BRTX) ha annunciato che fornirà un aggiornamento positivo sulla pipeline clinica prima dell'apertura del mercato giovedì 27 febbraio 2025. L'azienda di medicina rigenerativa, che si concentra su terapie a base di cellule staminali, condividerà ciò che il CEO Lance Alstodt descrive come "sviluppi chiave significativi" riguardo alla loro pipeline clinica.
Alstodt ha espresso entusiasmo per l'imminente annuncio, sottolineando che riflette "il lavoro molto solido del nostro team scientifico negli ultimi anni che sta dando i suoi frutti" e ha menzionato ulteriori eventi positivi legati a BRTX-100, uno dei prodotti dell'azienda.
L'azienda ospiterà una conference call in webcast alle 8:00 EST del 27 febbraio 2025, accessibile componendo il numero 888-506-0062 (US) o 973-528-0011 (Internazionale) con codice di accesso per i partecipanti 440089. La chiamata sarà anche trasmessa in diretta e archiviata nella sezione Investitori del sito web di BioRestorative.
BioRestorative Therapies (NASDAQ:BRTX) ha anunciado que proporcionará una actualización positiva sobre su pipeline clínico antes de la apertura del mercado el jueves 27 de febrero de 2025. La empresa de medicina regenerativa, que se centra en terapias basadas en células madre, compartirá lo que el CEO Lance Alstodt describe como "desarrollos clave significativos" en relación con su pipeline clínico.
Alstodt expresó entusiasmo por el próximo anuncio, señalando que refleja "el muy sólido trabajo de nuestro equipo científico en los últimos años que está dando sus frutos" y mencionó eventos positivos adicionales relacionados con BRTX-100, uno de los productos de la empresa.
La empresa llevará a cabo una conferencia telefónica por webcast a las 8:00 am EST del 27 de febrero de 2025, accesible marcando el 888-506-0062 (EE. UU.) o el 973-528-0011 (Internacional) con el código de acceso para participantes 440089. La llamada también se transmitirá en vivo y se archivará en la sección de Inversores del sitio web de BioRestorative.
BioRestorative Therapies (NASDAQ:BRTX)는 2025년 2월 27일 목요일 시장 개장 전에 긍정적인 임상 파이프라인 업데이트를 제공할 것이라고 발표했습니다. 줄기세포 기반 치료에 중점을 둔 재생 의학 회사는 CEO Lance Alstodt가 "의미 있는 주요 개발"이라고 설명하는 임상 파이프라인에 대한 정보를 공유할 예정입니다.
Alstodt는 다가오는 발표에 대해 열정을 표명하며, 이는 "지난 몇 년간 우리 과학 팀의 매우 견고한 작업이 결실을 맺고 있다"고 언급하며, 회사의 제품 중 하나인 BRTX-100과 관련된 추가 긍정적인 사건을 언급했습니다.
회사는 2025년 2월 27일 오전 8시 EST에 웹캐스트 회의 전화를 개최하며, 888-506-0062 (미국) 또는 973-528-0011 (국제)로 전화하여 참가자 액세스 코드 440089로 접속할 수 있습니다. 이 전화는 또한 생중계되며 BioRestorative 웹사이트의 투자자 섹션에 아카이브될 것입니다.
BioRestorative Therapies (NASDAQ:BRTX) a annoncé qu'elle fournira une mise à jour positive sur son pipeline clinique avant l'ouverture du marché le jeudi 27 février 2025. L'entreprise de médecine régénérative, qui se concentre sur les thérapies basées sur les cellules souches, partagera ce que le CEO Lance Alstodt décrit comme "des développements clés significatifs" concernant leur pipeline clinique.
Alstodt a exprimé son enthousiasme pour l'annonce à venir, notant qu'elle reflète "le travail très solide de notre équipe scientifique au cours des dernières années qui commence à porter ses fruits" et a mentionné des événements positifs supplémentaires liés à BRTX-100, l'un des produits de l'entreprise.
L'entreprise organisera une conférence téléphonique en webcast à 8h00 EST le 27 février 2025, accessible en composant le 888-506-0062 (États-Unis) ou le 973-528-0011 (International) avec le code d'accès des participants 440089. L'appel sera également diffusé en direct et archivé dans la section Investisseurs du site web de BioRestorative.
BioRestorative Therapies (NASDAQ:BRTX) hat angekündigt, dass es am Donnerstag, den 27. Februar 2025, vor Markteröffnung ein positives Update zur klinischen Pipeline bereitstellen wird. Das Unternehmen für regenerative Medizin, das sich auf stammzellbasierte Therapien konzentriert, wird das teilen, was CEO Lance Alstodt als "bedeutende Schlüsselentwicklungen" in Bezug auf ihre klinische Pipeline beschreibt.
Alstodt äußerte Begeisterung über die bevorstehende Ankündigung und stellte fest, dass sie "die sehr solide Arbeit unseres wissenschaftlichen Teams in den letzten Jahren widerspiegelt, die nun Früchte trägt" und erwähnte weitere positive Ereignisse im Zusammenhang mit BRTX-100, einem der Produkte des Unternehmens.
Das Unternehmen wird am 27. Februar 2025 um 8:00 Uhr EST eine webcast-konferenz veranstalten, die über die Nummer 888-506-0062 (USA) oder 973-528-0011 (International) mit dem Teilnehmerzugangscode 440089 zugänglich ist. Der Anruf wird auch live übertragen und im Investor-Bereich der BioRestorative-Website archiviert.
- Upcoming positive clinical pipeline update announcement
- Positive developments related to BRTX-100 product
- Years of scientific work coming to fruition according to CEO
- Specific details of the positive developments not yet disclosed
- Actual impact on company financials remains unknown until full announcement
MELVILLE, N.Y., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that it expects to provide a positive clinical pipeline update before market open on Thursday, February 27, 2025.
“We very much look forward to updating investors on some recent meaningful key developments with respect to our clinical pipeline and review some additional positive events related to BRTX-100 on Thursday,” said Lance Alstodt, Chief Executive Officer of BioRestorative. “We are thrilled to be in a position that reflects the very solid work of our scientific team over the last several years come to fruition and excited to see that positive momentum continue.”
Clinical Pipeline Update Conference Call & Webcast Details
BioRestorative management will host a webcasted conference call at 8:00am EST on Thursday, February 27, 2025. To participate in the conference call by telephone, please dial 888-506-0062 (United States) or 973-528-0011 (International), participant access code 440089. The call will also be broadcast live and archived on the Investor section of the Company’s website at https://www.biorestorative.com/investor-relations/.
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we have also recently begun offering BioCosmeceutical products:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via Investigational New Drug (IND)-enabling studies, with the aim of pioneering U.S. Food and Drug Administration (FDA) approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, and Form 10-Q filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
FAQ
What positive clinical pipeline update will BioRestorative Therapies (BRTX) announce on February 27, 2025?
What is BRTX-100 and how might it impact BioRestorative Therapies' stock?
How can investors participate in BioRestorative Therapies' (BRTX) February 27, 2025 conference call?
What areas of regenerative medicine does BioRestorative Therapies (BRTX) focus on?
What has been the recent progress of BioRestorative Therapies' (BRTX) scientific team?
